ArticleJapanese journal of radiology2026
Late urinary toxicity after prostate intensity-modulated radiation therapy for patients with history of invasive interventions for prostate or bladder.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate late genitourinary (GU) toxicities on receiving intensity-modulated radiation therapy (IMRT) in patients with prostate cancer (PCa) who had a history of invasive interventions for the prostate or bladder. MATERIALS AND
methodsAmong patients who received IMRT for PCa at our institution between August 2000 and December 2022, clinical outcomes among those with a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Cumulative incidence rates of late ≥ grade 2 and ≥ grade 3 GU and gastrointestinal toxicities, and rates of overall survival (OS) and biochemical failure-free survival (BFFS) were evaluated.
resultsA total of 32 consecutive patients were analyzed, among whom 28 received conventional fractionated IMRT with a median dose of 74 Gy in 37 fractions, and 4 underwent moderately hypo-fractionated IMRT with a median dose of 54 Gy in 15 fractions. The median follow-up period was 77.3 months after IMRT. Cumulative incidence rates of ≥ grade 2 and ≥ grade 3 GU toxicities were 20.7 and 4.3% at 5 years, and 26.4 and 4.3% at 8 years, respectively. More than 10 years after IMRT, 18.8% of patients developed ≥ grade 2 GU toxicities. OS and BFFS rates were 89.5 and 76.0% at 5 years, and 89.5 and 60.7% at 8 years, respectively.
conclusionProstate IMRT for patients with a history of invasive interventions for the prostate or bladder was considered a safe and feasible treatment option, although the incidence of late GU toxicities was relatively high. Long-term follow-up with close attention to the detection of GU toxicities is recommended for such a population. Clinical outcomes of IMRT in 32 patients with prostate cancer and a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Although the incidence of late genitourinary toxicities was relatively high, prostate IMRT was considered a safe and feasible treatment option for such a population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.